Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy

Abhimanyu S. Paraskar, Shivani Soni, Kenneth T. Chin, Padmaparna Chaudhuri, Katherine W. Muto, Julia Berkowitz, Michael W. Handlogten, Nathan Alves, Basar Bilgicer, Daniela M. Dinulescu, Raghunath A. Mashelkar, Shiladitya Sengupta

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-limited due to severe nephrotoxicity. Here we report the rational engineering of a novel nanoplatinate inspired by the mechanisms underlying cisplatin bioactivation. We engineered a novel polymer, glucosamine-functionalized polyisobutylene-maleic acid, where platinum (Pt) can be complexed to the monomeric units using a monocarboxylato and an O → Pt coordinate bond. We show that at a unique platinum to polymer ratio, this complex self-assembles into a nanoparticle, which releases cisplatin in a pH-dependent manner. The nanoparticles are rapidly internalized into the endolysosomal compartment of cancer cells, and exhibit an IC50 (4.25 ± 0.16 μM) comparable to that of free cisplatin (3.87 ± 0.37 μM), and superior to carboplatin (14.75 ± 0.38 μM). The nanoparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in breast and lung cancers and tumor regression in a K-ras LSL/+?Ptenfl/fl ovarian cancer model. Furthermore, the nanoparticle treatment resulted in reduced systemic and nephrotoxicity, validated by decreased biodistribution of platinum to the kidney as quantified using inductively coupled plasmaspectroscopy. Given the universalneedfor a better platinate, we anticipate this coupling of nanotechnology and structureactivity relationship to rationally reengineer cisplatin could have a major impact globally in the clinical treatment of cancer.

Original languageEnglish (US)
Pages (from-to)12435-12440
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number28
DOIs
StatePublished - Jul 13 2010
Externally publishedYes

Fingerprint

Structure-Activity Relationship
Nanoparticles
Cisplatin
Platinum
Neoplasms
Polymers
Breast Neoplasms
Nanotechnology
Carboplatin
Glucosamine
Ovarian Neoplasms
Inhibitory Concentration 50
Lung Neoplasms
Kidney
Drug Therapy
Therapeutics
Growth

Keywords

  • Cancer
  • Chemotherapy
  • Nanomedicine

ASJC Scopus subject areas

  • General

Cite this

Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. / Paraskar, Abhimanyu S.; Soni, Shivani; Chin, Kenneth T.; Chaudhuri, Padmaparna; Muto, Katherine W.; Berkowitz, Julia; Handlogten, Michael W.; Alves, Nathan; Bilgicer, Basar; Dinulescu, Daniela M.; Mashelkar, Raghunath A.; Sengupta, Shiladitya.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 28, 13.07.2010, p. 12435-12440.

Research output: Contribution to journalArticle

Paraskar, AS, Soni, S, Chin, KT, Chaudhuri, P, Muto, KW, Berkowitz, J, Handlogten, MW, Alves, N, Bilgicer, B, Dinulescu, DM, Mashelkar, RA & Sengupta, S 2010, 'Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy', Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 28, pp. 12435-12440. https://doi.org/10.1073/pnas.1007026107
Paraskar, Abhimanyu S. ; Soni, Shivani ; Chin, Kenneth T. ; Chaudhuri, Padmaparna ; Muto, Katherine W. ; Berkowitz, Julia ; Handlogten, Michael W. ; Alves, Nathan ; Bilgicer, Basar ; Dinulescu, Daniela M. ; Mashelkar, Raghunath A. ; Sengupta, Shiladitya. / Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 28. pp. 12435-12440.
@article{4e599cd38c7a430195e0aef0c45ea4fe,
title = "Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy",
abstract = "Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-limited due to severe nephrotoxicity. Here we report the rational engineering of a novel nanoplatinate inspired by the mechanisms underlying cisplatin bioactivation. We engineered a novel polymer, glucosamine-functionalized polyisobutylene-maleic acid, where platinum (Pt) can be complexed to the monomeric units using a monocarboxylato and an O → Pt coordinate bond. We show that at a unique platinum to polymer ratio, this complex self-assembles into a nanoparticle, which releases cisplatin in a pH-dependent manner. The nanoparticles are rapidly internalized into the endolysosomal compartment of cancer cells, and exhibit an IC50 (4.25 ± 0.16 μM) comparable to that of free cisplatin (3.87 ± 0.37 μM), and superior to carboplatin (14.75 ± 0.38 μM). The nanoparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in breast and lung cancers and tumor regression in a K-ras LSL/+?Ptenfl/fl ovarian cancer model. Furthermore, the nanoparticle treatment resulted in reduced systemic and nephrotoxicity, validated by decreased biodistribution of platinum to the kidney as quantified using inductively coupled plasmaspectroscopy. Given the universalneedfor a better platinate, we anticipate this coupling of nanotechnology and structureactivity relationship to rationally reengineer cisplatin could have a major impact globally in the clinical treatment of cancer.",
keywords = "Cancer, Chemotherapy, Nanomedicine",
author = "Paraskar, {Abhimanyu S.} and Shivani Soni and Chin, {Kenneth T.} and Padmaparna Chaudhuri and Muto, {Katherine W.} and Julia Berkowitz and Handlogten, {Michael W.} and Nathan Alves and Basar Bilgicer and Dinulescu, {Daniela M.} and Mashelkar, {Raghunath A.} and Shiladitya Sengupta",
year = "2010",
month = "7",
day = "13",
doi = "10.1073/pnas.1007026107",
language = "English (US)",
volume = "107",
pages = "12435--12440",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "28",

}

TY - JOUR

T1 - Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy

AU - Paraskar, Abhimanyu S.

AU - Soni, Shivani

AU - Chin, Kenneth T.

AU - Chaudhuri, Padmaparna

AU - Muto, Katherine W.

AU - Berkowitz, Julia

AU - Handlogten, Michael W.

AU - Alves, Nathan

AU - Bilgicer, Basar

AU - Dinulescu, Daniela M.

AU - Mashelkar, Raghunath A.

AU - Sengupta, Shiladitya

PY - 2010/7/13

Y1 - 2010/7/13

N2 - Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-limited due to severe nephrotoxicity. Here we report the rational engineering of a novel nanoplatinate inspired by the mechanisms underlying cisplatin bioactivation. We engineered a novel polymer, glucosamine-functionalized polyisobutylene-maleic acid, where platinum (Pt) can be complexed to the monomeric units using a monocarboxylato and an O → Pt coordinate bond. We show that at a unique platinum to polymer ratio, this complex self-assembles into a nanoparticle, which releases cisplatin in a pH-dependent manner. The nanoparticles are rapidly internalized into the endolysosomal compartment of cancer cells, and exhibit an IC50 (4.25 ± 0.16 μM) comparable to that of free cisplatin (3.87 ± 0.37 μM), and superior to carboplatin (14.75 ± 0.38 μM). The nanoparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in breast and lung cancers and tumor regression in a K-ras LSL/+?Ptenfl/fl ovarian cancer model. Furthermore, the nanoparticle treatment resulted in reduced systemic and nephrotoxicity, validated by decreased biodistribution of platinum to the kidney as quantified using inductively coupled plasmaspectroscopy. Given the universalneedfor a better platinate, we anticipate this coupling of nanotechnology and structureactivity relationship to rationally reengineer cisplatin could have a major impact globally in the clinical treatment of cancer.

AB - Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-limited due to severe nephrotoxicity. Here we report the rational engineering of a novel nanoplatinate inspired by the mechanisms underlying cisplatin bioactivation. We engineered a novel polymer, glucosamine-functionalized polyisobutylene-maleic acid, where platinum (Pt) can be complexed to the monomeric units using a monocarboxylato and an O → Pt coordinate bond. We show that at a unique platinum to polymer ratio, this complex self-assembles into a nanoparticle, which releases cisplatin in a pH-dependent manner. The nanoparticles are rapidly internalized into the endolysosomal compartment of cancer cells, and exhibit an IC50 (4.25 ± 0.16 μM) comparable to that of free cisplatin (3.87 ± 0.37 μM), and superior to carboplatin (14.75 ± 0.38 μM). The nanoparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in breast and lung cancers and tumor regression in a K-ras LSL/+?Ptenfl/fl ovarian cancer model. Furthermore, the nanoparticle treatment resulted in reduced systemic and nephrotoxicity, validated by decreased biodistribution of platinum to the kidney as quantified using inductively coupled plasmaspectroscopy. Given the universalneedfor a better platinate, we anticipate this coupling of nanotechnology and structureactivity relationship to rationally reengineer cisplatin could have a major impact globally in the clinical treatment of cancer.

KW - Cancer

KW - Chemotherapy

KW - Nanomedicine

UR - http://www.scopus.com/inward/record.url?scp=77955433242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955433242&partnerID=8YFLogxK

U2 - 10.1073/pnas.1007026107

DO - 10.1073/pnas.1007026107

M3 - Article

C2 - 20616005

AN - SCOPUS:77955433242

VL - 107

SP - 12435

EP - 12440

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 28

ER -